LENZ Therapeutics (GRPH) Stock Forecast, Price Target & Predictions
GRPH Stock Forecast
LENZ Therapeutics stock forecast is as follows: an average price target of $4.00 (represents a -82.03% downside from GRPH’s last price of $22.26) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
GRPH Price Target
The average price target for LENZ Therapeutics (GRPH) is $4.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $2.00. This represents a potential -82.03% downside from GRPH's last price of $22.26.
GRPH Analyst Ratings
According to 4 Wall Street analysts, LENZ Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for GRPH stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 4 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LENZ Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 03, 2023 | Morgan Stanley | $3.00 | $2.18 | 37.61% | -86.52% | |
| Jan 06, 2023 | RBC Capital | $4.00 | $3.06 | 30.72% | -82.03% | |
| Jan 06, 2023 | Leerink Partners | $2.00 | $3.06 | -34.64% | -91.02% | |
| Jan 06, 2023 | BMO Capital | $7.00 | $3.06 | 128.76% | -68.55% | |
| Jul 15, 2022 | Morgan Stanley | $6.00 | $3.30 | 81.82% | -73.05% |
The latest LENZ Therapeutics stock forecast, released on Feb 03, 2023 by Morgan Stanley company, set a price target of $3.00, which represents a 37.61% increase from the stock price at the time of the forecast ($2.18), and a -86.52% decrease from GRPH last price ($22.26).
LENZ Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $22.26 | $22.26 | $22.26 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of LENZ Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LENZ Therapeutics's last price of $22.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 03, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jan 06, 2023 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jan 06, 2023 | SVB Leerink | Market Perform | Downgrade | |
| Jan 06, 2023 | BMO Capital | Outperform | Market Perform | Downgrade |
| Jul 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jun 17, 2022 | BMO Capital | Outperform | Initialise | |
| Feb 18, 2022 | RBC Capital | Sector Perform | Initialise |
LENZ Therapeutics's last stock rating was published by Morgan Stanley on Feb 03, 2023. The company gave GRPH a "Equal-Weight" rating, the same as its previous rate.
LENZ Therapeutics Financial Forecast
LENZ Therapeutics Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
LENZ Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GRPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
LENZ Therapeutics EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict GRPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LENZ Therapeutics's previous annual EBITDA (undefined) of $NaN.
LENZ Therapeutics Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-424.58K | $-424.58K | $-471.76K | $-518.94K |
| High Forecast | $-424.58K | $-424.58K | $-471.76K | $-518.94K |
| Low Forecast | $-424.58K | $-424.58K | $-471.76K | $-518.94K |
| Surprise % | - | - | - | - |
LENZ Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GRPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
LENZ Therapeutics SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
LENZ Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GRPH last annual SG&A of $NaN (undefined).
LENZ Therapeutics EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.11 |
| High Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.11 |
| Low Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.11 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, LENZ Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GRPH previous annual EPS of $NaN (undefined).
LENZ Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.48 | $5.50 | 1045.83% | Buy |
| TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| ACHL | Achilles Therapeutics | $0.97 | $2.00 | 106.19% | Buy |